Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Chloroquine and hydroxychloroquine ototoxicity; potential implications for SARS-CoV-2 treatment. A brief review of the literature

Pietro De Luca a,*, Alfonso Scarpa a, Egidio De Bonis a, Matteo Cavaliere b, Pasquale Viola c, Federico Maria Gioacchini d, Massimo Ralli e, Cassandro Ettore a, Cassandro Claudia f

a Department of Medicine, Surgery and Dentistry, University of Salerno, Salerno, Italy
b Otolaryngology Department, University Hospital “San Giovanni di Dio e Ruggi D’Aragona” Salerno, Italy
c Unit of Audiology, Department of Experimental and Clinical Medicine, Regional Centre for Cochlear Implants and ENT Diseases, University “Magna Graecia”, Catanzaro, Italy
d ENT Unit, Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona, Italy
e Department of Sense Organs, University “Sapienza”, Rome, Italy
f Department of Surgical Sciences, University of Turin, Turin, Italy

ARTICLE INFO

Keywords:
COVID-19
Ototoxicity
Chloroquine
Hydroxychloroquine
Hearing loss
Tinnitus

ABSTRACT

Introduction: Current clinical evidences do not support any specific treatment against SARS-CoV-2. Chloroquine (CQ) and hydroxychloroquine (HCQ) are typically used in the treatment of rheumatoid arthritis, systemic lupus erythematosus and malaria; they have been considered for off-label and compassionate use in several countries against moderate to severe cases of COVID-19 and there’s actually a massive demand of these two drugs. The aim of this paper is to briefly review the published literature, summarizing evidences about audiological implications after CQ and HCQ treatment.

Methods: We conducted a review of the literature on Medline and Pubmed platforms from 27th May 2020 to 30 May 2020. We combined MeSH terms of “chloroquine”, “hydroxychloroquine”, “ototoxicity”, “hearing loss”, “tinnitus”, “deafness” and “hearing”. Publications with relevant data were included. Selected data (authors, country and year; sample size; study design; audiological side effects) were extracted and summarized in a table.

Results: Of 45 initial studies, 14 met inclusion criteria. The authors found xix cases of HCQ ototoxicity; Tinnitus was reported in 2 cases, and it was found to be reversible or irreversible. Sensorineural hearing loss after HCQ use was reported in 7 patients; it was found to be irreversible or partially reversible after discontinuation of HCQ in 6 cases. Eight papers reporting CQ ototoxicity were; tinnitus was not reported by any authors. Sensorineural hearing loss after taking CQ was reported in 6 patients; it was found to be irreversible after discontinuation of CQ in 5 patients. One patient showed abnormal gait after a single intramuscular injection of CQ. Thirteen patients’ Auditory Brainstem Response (ABR) were found to be abnormal, but they resolved after CQ discontinuation.

Conclusions: CQ and HCQ related ototoxicity is widely reported in the literature although the pathophysiological mechanism is not well known. Current data are not sufficient enough to support the use of CQ and HCQ as therapy for COVID-19, but considering the growing demand for these two drugs and the number of people around the world who have taken and will take CQ and HCQ, it must necessarily consider the clinical and social impact of long term audiological side effects.

1. Introduction

The Severe Acute Respiratory Syndrome-CoronaVirus-2 (SARS-CoV-2), also known as COVID-19 pandemic, is engaging clinicians around the world in an unprecedented effort and is forcing the resilience of healthcare systems [1]. Current clinical evidences do not support any specific treatment against SARS-CoV-2 [2,3].

Chloroquine (CQ) and hydroxychloroquine (HCQ), quinine-related compounds, are typically used in the treatment of rheumatoid arthritis, systemic lupus erythematosus and malaria; they have been considered for off-label and compassionate use in several countries against moderate to severe cases of COVID-19 and there’s actually a
massive demand of these two drugs.

Several studies indicated that CQ and HCQ show antagonism against COVID-19 in vitro [4]; there are actually over 70 clinical trials that have shown poor evidences regarding the effects of these drugs in patients.

Commons side effects of CQ and HCQ reported in literature are hearth rhythm problems, liver and kidney problems, hypoglycaemia, retinopathy, muscle weakness [5]. The literature also contains case reports of ototoxicity (hearing loss, tinnitus) due to the damage of inner ear structures [6].

The aim of this paper is to briefly review the published literature, summarizing evidences about audiological implications after CQ and HCQ treatment, and draw conclusions about potential implications in COVID-19 patients treated with CQ and HCQ.

2. Methods

We conducted a review of the literature on Medline and Pubmed platforms from 27th May 2020 to 30 May 2020. We combined MeSH terms of “chloroquine”, “hydroxychloroquine”, “ototoxicity”, “hearing loss”, “tinnitus”, “deafness” and “hearing”. Publications with relevant data were included. Selected data (authors, country and year; sample size; study design; audiological side effects) were extracted and summarized in a table.

Table 1
Hydroxychloroquine ototoxicity.

| Author, country, year | Sample size | Age, y/ gender | Disease | Study design and dosage of Hydroxychloroquine (HQ) | Results |
|-----------------------|-------------|----------------|---------|---------------------------------------------------|---------|
| Seckin et al, Turkey, 2000 | 1 | 34 yr/Male | Rheumatoid arthritis | Case report; 400 mg/day | After six months of combination therapy, he developed tinnitus and bilateral mild sensorineural hearing loss. Tinnitus vanished two weeks after withdrawal of HQ; two months lateral symptoms of hearing loss had improved (the follow-up audiogram was normal) |
| Khalili et al, Iran, 2014 | 1 | 57 yr/Male | Rheumatoid arthritis in HIV + | Case report; 200 mg/day | Bilateral moderate to severe sensorineural hearing loss one months after HQ; two months after discontinuation of HQ, the follow-up audiogram showed mild to moderate sensorineural hearing loss |
| Fernandes et al, Brazil, 2018 | 1 | 51 yr/ Female | Systemic lupus erythematosus | Case report; 400 mg/day | Three years after use of HQ she complained tinnitus and moderate SNHL on left ear and mild to moderate on right ear. This condition persisted after discontinuation of HQ |
| Coutinho and Duarte, Portugal, 2001 | 1 | 7 yr/ Female | Idiopathic pulmonary haemosiderosis | Case report; 200 mg/day | She had progressive hearing loss in the right ear two years after sustained HQ use. Auditory Brainstem Response test showed no response at 90 dB in the right ear |
| Lim and Tang, Malaysia, 2011 | 1 | 11 yr/ Female | Systemic lupus erythematosus | Case report; 100 mg/daily | Bilateral low-frequencies hearing loss two months after HQ use |
| Johansen and Gran, Norway, 1998 | 2 | 44 yr/1 Male, 1 Female | Systemic lupus erythematosus | Data not available | Irreversible sensorineural hearing loss several years after HQ use |

Table 2
Chloroquine ototoxicity.

| Author, country, year | Sample size | Age, y/ gender | Disease | Study design and dosage of Hydroxychloroquine (HQ) | Results |
|-----------------------|-------------|----------------|---------|---------------------------------------------------|---------|
| Mukherjee and Enugu, Nigeria, 1979 | 1 | 6 yr/Female | Malaria | Case report; 250 IM mg/ day × 7 days | Severe unilateral hearing loss, improved after prednisolone injection |
| Mazz and Naunton, United States, 1968 | 1 | 7 yr/Male | The mother took chloroquine, during the first trimester of pregnancy for Systemic Lupus Erythematosus. The boy died from an epithelial endymoma of the right cerebellum | Case report; 250 mg/day | Profound sensorineural hearing loss. Post-mortem inner ear examination showed complete absence of the inner and outer hair cells throughout all of the turns of the cochlea |
| Hart and Naunton, United States, 1963 | 2 | 5 yr/Male, 3 yr/Male | The mother took chloroquine during both pregnancies | Case reports; 250 mg/day | Severe bilateral cochleovestibular paresis |
| Hadi et al, United States, 1995 | 1 | 2.5 yr/Male | Malaria | Case report; 65 mg (single IM therapeutic dose) | Abnormal gait few our after chloroquine injection; hearing loss on 2nd day. Persistent hearing loss three and five years after chloroquine injection |
| Dwivedi and Mehra, India, 1978 | 1 | 52 yr/Male | Malaria | Case report; 1000 mg os | Bilateral permanent and profound deafness 1.5 h after taking chloroquine |
| Bortoli and Santiago, Brazil, 2007 | / | / | / | Review of the literature | Sensorineural hearing loss and tinnitus were described as side effects after taking chloroquine |
| Borba et al, Brazil, 2004 | 9 | Data not available | Mothers took chloroquine during first trimester of pregnancy | Case-control study, 250 mg/day | No significant difference in hearing threshold by pure tone audiometry of children between exposure group and control (non-exposure) group |
| Bernard, Canada, 1985 | 74 | From 18 to 50 yr (39 yr median) | 70 case of Rheumatoid Arthritis and 4 cases of Systemic Lupus Erythematosus | Observational study; 205 mg/day | No hearing change in pure tone audiology. Thirteen case of abnormal ABR, resolved after discontinuation of chloroquine |
3. Results

3.1. Hydroxychloroquine ototoxicity

Six cases of HCQ ototoxicity, from 1998 to 2018, were identified and summarized in Table 1. Tinnitus was reported in 2 cases [7,8], and it was found to be reversible [7] or irreversible [8]. Sensorineural hearing loss after HCQ use was reported in 7 patients (three males, four females; five adults, two children) [7–12]; the onset of hearing loss after HCQ treatment varied from 1 month [9] to several years [8,10,12]. It was found to be irreversible or partially reversible after discontinuation of HCQ in 6 cases [8–12]. Systemic Lupus Erythematosus (three patients) [8,11,12] and Rheumatoid Arthritis (two patients) [7,9] were the most common diseases for which patients took HCQ.

3.2. Chloroquine ototoxicity

Eight papers, from 1963 to 2007, reporting CQ ototoxicity were identified and summarized in Table 2. The complessive sample size of the works was 91 patients; there were 5 case reports [13–17], 1 case-control study [18], 1 review article [19], 1 observational study [20]. Tinnitus was no reported by any authors. Sensorineural hearing loss after taking CQ was reported in 6 patients (five males, one female; one adult, five children) [13–17,19]. It was found to be irreversible or partially reversible after discontinuation of CQ in 5 patients [13,15–17]. One patient showed abnormal gait after a single intra-muscular injection of CQ [17]. Thirteen patients’ Auditory Brainstem Response (ABR) were found to be abnormal, but they resolved after CQ discontinuation [20].

4. Discussion

Sensorineural hearing loss, tinnitus and balance involvement are possible side effects of CQ and HCQ, as reported in medical literature; in addition, the use of this drugs can worst a prior hearing loss. CQ and HCQ are commonly used against malaria (10 mg/kg at the beginning, then 5 mg/kg after 6–24–48 h) [21] and some autoimmune diseases as systemic lupus erythematosus or rheumatoid arthritis (400 or 600 mg/day); we should consider other possible causes of hearing loss, as the autoimmunity itself.

The exact mechanism of CQ and HCQ related ototoxicity is not well established; it is probably related to the destruction of steroildia and the reduction of the neutron population; therefore, quinine-related compounds showed a long-term retention in melanocytes of inner ear, and this could explain the late onset of lesions and symptoms.

Hennebert and Fernandez [22] demonstrated that the quinine injected into the middle ear of guinea pigs produced signs of temporary unilatera labyrinthectomy; hair cells, limbus an stria vascularis were the most involved inner ear structure, particularly near the round window. In addition, Gradenigo [23] and Wittmaack et al. [24] suggested the possibility of vasoconstriction for ototoxicity.

Most of the literature on this topic is not recent; therefore, there are only case reports and a few observational studies. Larger study with rigorous methodology should needed to obtain reliable data about audiological implication.

Several registered clinical trials are being conducted to assess the effectiveness of CQ and HCQ against COVID-19 pandemic; the dose of CQ used in these trials is higher than dosage of CQ reported for malaria treatment [25]. Most authors suggested a total dosage of 1 g daily for 10 days for the treatment of SARS-CoV-2. In addition, the duration of treatment against SARS-CoV-2 is substantially shorter than treatment period in patients with chronic autoimmune disease (months or even years).

No ototoxicity or cochleovestibular side effects are described in recent trial, but we should also consider two issues: 1) otological side effects often appear at a distant of months or years from CQ or HCQ discontinuation (especially HCQ ototoxicity), and 2) should be separately assessed the role of the other drugs used in treatment protocols with CQ and HCQ.

The use of CQ and HCQ during pregnancy has remained controversial for a long time. It is generally considered safe in pregnant women [26] but it should be administered with caution in the first trimester of pregnancy because it can lead to cochleovestibular abnormalities in newborns [15].

Costedoat-Chalumeau et al. [27] concluded that HCQ can be maintained throughout pregnancy in patients with systemic lupus erythematosus. In Zhou et al. opinion’s HCQ showed less side effects than CQ due to its safer profile in pregnancy [28]; this point is also confirmed by Zhao et al. [29]. A recent work by Lacroix et al. [30] didn’t report any otological abnormalities in newborns; therefore they recommend to remember to a woman who took HCQ or CQ that she will remain exposed up to 210 days for CQ and 420 days for HCQ after their discontinuation.

5. Conclusions

CQ and HCQ related ototoxicity is widely reported in the literature although the pathophysiological mechanism is not well known. Current data are not sufficient enough to support the use of CQ and HCQ as therapy for COVID-19, but considering the growing demand for these two drugs and the number of people around the world who have taken and will take CQ and HCQ, it must necessarily consider the clinical and social impact of audiological side effects in the long term.

Pure-tone audimetry evaluation should be assessed in patients treated with CQ or HCQ, especially in patients with a poor hearing function, which could benefit from the use of antioxidant drugs for the protection of cochlear sensory.

Source of funding

No funding source to declare.

Declaration of competing interest

The authors have no conflict of interest to disclose.

References

[1] De Luca P, Scarpa A, Ralli M, Nasal, pharyngeal and laryngeal endoscopy procedures during COVID-19 pandemic. Available recommendations from national and international societies. Eur Arch Otorhinolaryngol 2020 May 6;1–3. https://doi.org/10.1007/s00405-020-06028-1.

[2] De Luca P, Colacurcio V, De Bonis E. Impact of the COVID-19 pandemic on otorhinolaryngology residencies: a real-life experience. Eur J Otorhinolaryngol J 2020;145561320926291. https://doi.org/10.1177/014561320926291. [My 18].

[3] Arshad Ali S, Baloch M, Ahmed N, Arshad Ali A, Iqbal A. The outbreak of Coronavirus Disease 2019 (COVID-19)—an emerging global health threat. J Infect Public Health 2020;13(4):e44-6. https://doi.org/10.1016/j.jiph.2020.02.033.

[4] Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020;30:269-71. https://doi.org/10.1038/s41422-020-0282-6.

[5] Wittes R. Adverse reactions to chloroquine and amodiaquine as used for malaria prophylaxis: a review of the literature. Can Fam Physician 1987 Nov;33:264–9.

[6] Cianfriere G, Pentangelo D, Cianfriere F, et al. Pharmacological drugs inducing ototoxicity, vestibular symptoms and tinnitus: a reasoned and updated guide. Eur Rev Med Pharmacol Sci 2011;15:601-36.

[7] Seçkin U, Ozoran K, Kirciogullari A, et al. Hydroxychloroquine ototoxicity in a patient with rheumatoid arthritis. Rheumatol Int 2000;19(5):203-4. https://doi.org/10.1007/s002960000054.

[8] de Novaes Fernandes MB, Soares DRR, Thien CI, et al. Hydroxychloroquine ototoxicity in a patient with systemic lupus erythematosus. An Bras Dermatol 2018;93(3):469-70. https://doi.org/10.1590/sabd1065-4841.20187615. Jun.

[9] Khalili H, Dastan F, Manshadi SAD. A case report of hearing loss post use of hydroxychloroquine in a patient with rheumatoid arthritis. J Pediatr Otorhinolaryngol 2002 Jan 11;62(1):53-7. https://doi.org/10.1016/s0165-5876(01)00692-4.
[11] Lim SC, Tang SP. Hydroxychloroquine-induced ototoxicity in a child with systemic lupus erythematosus. Int J Rheum Dis 2011 Feb;14(1):e1–2. https://doi.org/10.1111/j.1756-185X.2010.01582.x.

[12] Johansen PB, Gran JT. Ootoxicity due to hydroxychloroquine: report of two cases. Clin Exp Rheumatol 1998;16(4):472–4. ul-Aug.

[13] Dwivedi GS, Mehra YN. Ootoxicity of chloroquine phosphate a case report. J Laryngol Otol 1978 Aug;92(8):701–3. https://doi.org/10.1017/s0022215100085960.

[14] Mukherjee Dk. Chloroquine ototoxicity—a reversible phenomenon? J Laryngol Otol 1979 Aug;93(8):809–15. https://doi.org/10.1017/s0022215100087740.

[15] Matz GJ, Naunton RF. Ootoxicity of chloroquine. Arch Otolaryngol 1968;88 (4):370–2. https://doi.org/10.1001/archotol.1968.00770010372008.

[16] Hart CW, Naunton RF. The ototoxicity of chloroquine phosphate. Arch Otolaryngol 1964 Oct;80:407–12. https://doi.org/10.1001/archotol.1964.00750040419009.

[17] Hadi U, Nuwayhid N, Hasbini AS. Chloroquine ototoxicity: an idiosyncratic phenomenon. Otolaryngol Head Neck Surg 1996 Mar;114(3):491–3. https://doi.org/10.1016/s0194-5998(96)70226-7.

[18] Borba EF, Turrini-Filho JR, Kuruma KA, et al. Chloroquine gestational use in systemic lupus erythematosus: assessing the risk of child otoxicity by pure tone audiometry. Lupus 2004;13(4):223–7. https://doi.org/10.1191/0961203304lc328oc.

[19] Bortoli R, Santiago M. Chloroquine ototoxicity. Clin Rheumatol 2007 Nov;26(11):1809–10. https://doi.org/10.1007/s10067-007-0662-6 [Epub 2007 Jun 27].

[20] Bernard Philippe. Alterations of auditory evoked potentials during the course of chloroquine treatment. Acta Oto-Laryngologica 1985;99(3-4):387–92. https://doi.org/10.3109/00016488509108928.

[21] Reyburn H. New WHO guidelines for the treatment of malaria. BMJ 2010 May 28; 340:c2637. https://doi.org/10.1136/bmj.c2637.

[22] Hennebert D, Fernandez C. Ootoxicity of quinine in experimental animals. Arch Otolaryngol Head Neck Surg 1985;70(3):321–3 [doi: 10.1001/archotol.1959.00730040329006].

[23] Gradenigo G. Krankheiten des Labyrinths und des Nervus acusticus. In: Handbuch der Ohrenheilkunde. H. F. C. W. Vogel, Leipzig; hrsg. H. Schwartze. vols. 474–479; 1892. p. 352–3.

[24] Wittmaack K. Beitrag zur Kenntnis der Wirkung des Chinins auf das Gehörorgan. Pflügers Arch ges Physiol 1903;70:209–33.

[25] Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020;14:72–3. https://doi.org/10.5582/bst.2020.01047.

[26] Parke A. Antimalarial drugs in pregnancy. Scans J Rheumatol Suppl 1998;107:125–7. https://doi.org/10.1191/03009742.1998.11720786.

[27] Costedoat-Chalumeau N, Amoura Z, Huong DLT et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Rev Lit, [Autoimm Reviews].

[28] Zhou D, Dai SM, Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother 2020 Mar 20;doi:114. https://doi.org/10.1093/jac/dkaa114.

[29] Zhao X, Jiang Y, Zhao Y, et al. Analysis of the susceptibility to COVID-19 in pregnancy and recommendations on potential drug screening. Eur J Clin Microbiol Infect Dis 2020 Apr 23:1–12. https://doi.org/10.1007/s10096-020-03897-6.

[30] Lacroix I, Benevent J, Damase-Michel C. Chloroquine and hydroxychloroquine during pregnancy: what do we know? Therapies 2020;21(1):513. https://doi.org/10.1016/j.therap.2020.05.004.